Search clinical trials for: AMG 162 / Denosumab

Total 5766 results

National Cancer Institute (NCI)

Terminated

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

Ovarian Carcinoma

United States, Israel
Amgen

Completed

A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

Osteoporosis
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Recurrent Osteosarcoma | Refractory Osteosarcoma | Stage IV Osteosarcoma AJCC v7 | Stage IVA Osteosarcoma AJCC v7 | Stage IVB Osteosarcoma AJCC v7 | Metastatic Osteosarcoma

United States, Canada, Puerto Rico
Amgen

Completed

Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France (PILOTE)

Post Menopausal Osteoporosis

France
Roswell Park Cancer Institute
Amgen

Completed

Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

Osteoporosis | Osteopenia | Allogeneic Hematopoietic Stem Cell Transplantation Recipient

United States
Amgen

Completed

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

Breast Cancer | Osteopenia | Low Bone Mineral Density
Northwestern University
National Cancer Institute (NCI); Amgen

Terminated

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Stage IV Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Breast Carcinoma Metastatic in the Bone | Circulating Tumor Cell Count

United States
Daiichi Sankyo, Inc.

Completed

AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment (DESIRABLE)

Rheumatoid Arthritis

Japan
Amgen

Completed

Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis

Osteoporosis | Osteopenia
Amgen

Completed

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

Prostate Cancer
Amgen

Completed

An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density

Low Bone Mineral Density
GlaxoSmithKline

Completed

A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)

Asthma

Germany, South Africa, Bulgaria
Amgen

Completed

Study of Transitioning From Alendronate to Denosumab

Postmenopausal Osteoporosis
Amgen

Completed

Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

Bone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast Cancer | Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

United Kingdom, Czech Republic
Amgen

Completed

Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates

Bone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast Cancer | Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
M.D. Anderson Cancer Center
Amgen

Terminated

Denosumab for Breast Cancer With Bone Mets

Breast Cancer

United States
Amgen

Completed

Multiple Dose Study to Evaluate the Safety of Multiple Doses of Denosumab 120 mg in Adults With Severe Chronic Kidney Disease (CKD) and CKD on Dialysis

Renal Impairment

United States
Amgen

Completed

Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis

Postmenopausal Osteoporosis
Amgen

Completed

Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer

Breast Cancer | Metastases | Bone Metastases in Subjects With Advanced Breast Cancer
Amgen

Completed

Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis
Amgen

Completed

A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis

Osteoporosis
Amgen

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women

Osteoporosis
J2H Biotech

Completed

Phase 1 Study to Investigate Safety, Tolerability, PK/PK of J2H-1702 in Healthy Males

Non-alcoholic Steatohepatitis

Korea, Republic of
Hope Rugo, MD
University of California, San Francisco; Amgen

Terminated

Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer

Early Stage Breast Cancer

United States
Amgen

Completed

Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density

Low Bone Mineral Density
Amgen
Daiichi Sankyo, Inc.

Completed

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Cancer | Multiple Myeloma | Bone Metastases | Hematologic Malignancies | Oncology | Multiple Myeloma Bone Lesions

United States, Germany, Italy, Spain, Canada, France, Czechia, Hungary, Korea, Republic of, Russian Federation, United Kingdom, Taiwan, Australia, Hong Kong, New Zealand, Austria, Slovakia, Portugal, Greece, Bulgaria, Poland, Ukraine and more
Amgen

Completed

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

Post Menopausal Osteoporosis

Canada, Denmark, United States, Belgium, Poland, Spain, Australia
RenJi Hospital
Shanghai JMT-Bio Inc.

Not yet recruiting

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Multiple Myeloma | Bone Diseases
UniQure Biopharma B.V.

Not yet recruiting

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Amyotrophic Lateral Sclerosis

United States
Amgen

Terminated

Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer

NSCLC | Non-small Cell Lung Cancer

United States, Austria, Australia
Helixmith Co., Ltd.

Completed

Safety Study of Gene Therapy in Treating Lower Leg Ischemia

Critical Limb Ischemia

United States
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.

Completed

Pharmacokinetic Study of KHK7580 in Healthy Adult Volunteers

Healthy Volunteer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

Metastatic Malignant Neoplasm | Advanced Malignant Neoplasm | Recurrent Malignant Neoplasm | Refractory Malignant Neoplasm

United States
Amgen

Completed

Study of Denosumab in Subjects With Giant Cell Tumor of Bone

Cancer | Giant Cell Tumor of Bone | Giant Cell Tumors | Benign Giant Cell Tumors

United States, Canada, Sweden, Poland, Germany, Netherlands, Australia, Italy, Austria, Spain, France, United Kingdom
Can-Fite BioPharma

Completed

Safety and Efficacy Study of CF101 to Treat Psoriasis

Plaque Psoriasis

Israel
GlaxoSmithKline

Completed

A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of, Malaysia, Philippines, Thailand, Russian Federation, Mexico
Amgen

Completed

Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004

Giant Cell Tumor of Bone

Australia, France, United States, Spain, Italy, Poland, Sweden, United Kingdom
Amgen

Completed

A First-in-human Study Evaluating AMG 167 in Healthy Men and Postmenopausal Women

Osteopenia
Johns Hopkins University
Cultivate Biologics

Completed

The Pharmacokinetics and Pharmacodynamics of a Single Acute Dose of a Hemp-derived Oral Product With a 1:1 Ratio of CBD:CBD-A

Cannabis

United States
Amgen

Completed

AMG 172 First in Human Study in Patients With Kidney Cancer

Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell Adenocarcinoma

France, United States, Germany
Yuhan Corporation

Completed

Phase 1/2a Trial of YH12852 in Healthy Subjects and Patients With Functional Constipation

Functional Constipation

Korea, Republic of
Amgen

Terminated

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Diffuse Large B-cell Lymphoma(DLBCL)

United States, Canada, Germany, Belgium
Pfizer

Completed

Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691

Hepatitis C Virus

United States
Hangzhou Grand Biologic Pharmaceutical, Inc.
Peking Union Medical College Hospital

Unknown

Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of of HZBio1 in Healthy Subjects

Healthy Participants

China
Turku University Hospital
Amgen

Completed

Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women (ProliaHip)

Hip Osteoarthritis

Finland
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
University of Edinburgh
NHS Lothian

Completed

Cardiovascular Effects of Apelin In Healthy Volunteers

Healthy

United Kingdom
Otsuka Pharmaceutical Co., Ltd.

Recruiting

A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])

Cardiac Edema (CHF)

Japan
University of Southampton

Not yet recruiting

Attentional Bias Modification Training for People With Chronic Musculoskeletal Pain (I-ABMT)

Chronic Pain

United Kingdom
Technical University of Munich

Completed

Comparison of AMG and EMG to Avoid Residual Paralysis After General Anesthesia (CAMEM)

Anaesthesia | Respiratory Paralysis | Observation of Neuromuscular Block

Germany

Search clinical trials for: AMG 162 / Denosumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations